Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation

Y. Li, T. Yokota, V. Gama, T. Yoshida, J. A. Gomez, K. Ishikawa, H. Sasaguri, H. Y. Cohen, D. A. Sinclair, H. Mizusawa, S. Matsuyama

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


Polyglutamine (polyQ) diseases, such as Huntington's disease and Machado-Joseph disease (MJD), are caused by gain of toxic function of abnormally expanded polyQ tracts. Here, we show that expanded polyQ of ataxin-3 (Q79C), a gene that causes MJD, stimulates Ku70 acetylation, which in turn dissociates the proapoptotic protein Bax from Ku70, thereby promoting Bax activation and subsequent cell death. The Q79C-induced cell death was significantly blocked by Ku70 or Bax-inhibiting peptides (BIPs) designed from Ku70. Furthermore, expression of SIRT1 deacetylase and the addition of a SIRT1 agonist, resveratrol, reduced Q79C toxicity. In contrast, mimicking acetylation of Ku70 abolished the ability of Ku70 to suppress Q79C toxicity. These results indicate that Bax and Ku70 acetylation play important roles in Q79C-induced cell death, and that BIP may be useful in the development of therapeutics for polyQ diseases.

Original languageEnglish
Pages (from-to)2058-2067
Number of pages10
JournalCell Death and Differentiation
Issue number12
StatePublished - 1 Dec 2007
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation'. Together they form a unique fingerprint.

Cite this